These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37708797)

  • 1. Current advances and development strategies of orally bioavailable PROTACs.
    Zeng S; Ye Y; Xia H; Min J; Xu J; Wang Z; Pan Y; Zhou X; Huang W
    Eur J Med Chem; 2023 Dec; 261():115793. PubMed ID: 37708797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery.
    Whitehurst BC; Bauer MR; Edfeldt F; Gunnarsson A; Margreitter C; Rawlins PB; Storer RI
    J Med Chem; 2023 Jun; 66(11):7594-7604. PubMed ID: 37224440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
    Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
    Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.
    Edmondson SD; Yang B; Fallan C
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1555-1564. PubMed ID: 31047748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).
    Tomoshige S; Ishikawa M
    Bioorg Med Chem; 2021 Jul; 41():116221. PubMed ID: 34034148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in AR-targeting chimeras: a case study of proteolysis-targeting chimeras from bench to bedside.
    Du W
    Future Med Chem; 2022 Oct; 14(20):1471-1489. PubMed ID: 36214138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible Assembly of Proteolysis Targeting Chimeras.
    Gui W; Giardina SF; Balzarini M; Barany F; Kodadek T
    ACS Chem Biol; 2023 Jul; 18(7):1582-1593. PubMed ID: 37422908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
    Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs).
    Saraswat AL; Vartak R; Hegazy R; Patel A; Patel K
    Drug Discov Today; 2023 Jan; 28(1):103387. PubMed ID: 36184017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
    Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments of PROTACs technology in immune-related diseases.
    Wang C; Zhang Y; Deng J; Liang B; Xing D
    Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.
    Mi D; Li Y; Gu H; Li Y; Chen Y
    Eur J Med Chem; 2023 Aug; 256():115444. PubMed ID: 37178483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.